Polymer composites with enhanced electrochemical properties and their application in non-small cell lung cancer treatment

Cancer, particularly non-small cell lung cancer (NSCLC), remains a leading cause of cancer-related deaths, with a dismal 5-year survival rate of approximately 15 %. This underscores the urgent need for novel, safe, and effective targeted therapies. In this study, we synthesized compound 1 for lung cancer treatment, considering the challenges in drug delivery. A new three-dimensional (3D) La(III)-based coordination polymer with the chemical composition of {[La(L)(H₂O)₃]Cl·H₂O}_n (1) (H₂L = (4-(pyridyl-N-oxide)methylphosphonic acid), was successfully self-assembled via diffusion method at room temperature and characterized by single-crystal X-ray diffraction, elemental analyses and FT-IR. Following this, we developed a composite drug delivery material, PCL-CB@CP1@1, and assessed its inhibitory effects on NSCLC cell proliferation. The results demonstrated that PCL-CB@CP1@1 effectively inhibited cell growth by modulating the Nrf2/HO-1/GPX4 signaling pathway. Additionally, molecular docking simulations indicated multiple binding interactions between the La(III) complex and receptor sites, further highlighting its significant biological activity. These findings suggest that PCL-CB@CP1@1 holds potential as a targeted therapeutic agent for lung cancer treatment, offering new possibilities for improving patient outcomes.